Top Markets
Coin of the day
Damora Therapeutics, Inc. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA
Rank in Stocks #6695
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering... Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jรถrgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgรฅrd Schambye, its corporate operations are based in Boston, Massachusetts.
Share Price
$30.90
Market Cap
$1.90B
Change (1 day)
1.68%
Change (1 year)
819.64%
Country
US
Trade Damora Therapeutics, Inc. (DMRA)

Category

P/S ratio for Damora Therapeutics, Inc. (DMRA)
P/S ratio as of 2026 TTM: 0
According to Damora Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Damora Therapeutics, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH